效应器
细胞生物学
染色质
组蛋白
乙酰化
细胞毒性T细胞
CTL公司*
生物
CD8型
肿瘤微环境
化学
癌症研究
T细胞
免疫系统
调解人
癌症免疫疗法
线粒体
表观基因组
组蛋白H3
染色质重塑
串扰
免疫疗法
线粒体DNA
表观遗传学
激酶
免疫
作者
Silvia Tiberti,Sara Gennari,Martina Romeo,Ilir Sheraj,Mohamed Faisal Kassir,Juan Fernández-García,Carina B. Nava Lauson,Roberta Noberini,Carlotta Catozzi,Tiziano Dallavilla,Mattia Ballerini,Alessia Loffreda,Simona G. Codreanu,Stacy D. Sherrod,Katrina L. Leaptrot,Alexandra C. Schrimpe-Rutledge,John A. McLean,Martin H. Schaefer,Simona Rodighiero,Tiziana Bonaldi
出处
期刊:Science immunology
[American Association for the Advancement of Science]
日期:2026-03-27
卷期号:11 (117): eaeb1459-eaeb1459
标识
DOI:10.1126/sciimmunol.aeb1459
摘要
Lipid accumulation in the tumor microenvironment is a hallmark of solid tumors, with increased palmitate (PA) availability fostering tumor progression. Although PA's direct effects on cancer cells are well described, its impact on CD8 T cells [cytotoxic T lymphocytes (CTLs)] remains unclear. Here, we show that PA irreversibly impairs CTL mitochondrial metabolism, leading to the loss of effector functions and compromised antitumor immunity. PA-induced mitochondrial dysfunction reduced histone acetylation and chromatin accessibility, suppressing transcription of genes involved in T cell replication and effector programs. We identified sphingosine kinase 2 (SPHK2) as a key mediator of PA-induced dysfunction, with pharmacological inhibition of SPHK2 restoring mitochondrial fitness, rescuing CTL effector function, and promoting antitumor activity. These findings uncover a distinct mechanism by which PA drives immune evasion in tumors and highlight SPHK2 as a potential therapeutic target to enhance T cell-based immunotherapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI